Sarepta Therapeutics (SRPT) Posts Q2 Loss of 85c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Sarepta Therapeutic (SRPT) Eteplirsen NDA Filing on Track for Year-End, Needham & Company
August 7, 2014 11:55 AM EDTNeedham & Company analyst Chad Messer, Ph.D reiterated a Buy rating and $52 price target on Sarepta Therapeutic (NASDAQ: SRPT) following Q2 results, noting Eteplirsen NDA filing is on track for year end.
Messer commented, "Management provided a detailed clinical and regulatory update on eteplirsen and follow-on exon skipping drugs for DMD on Sarepta's 2Q:14 earnings call. The bottom line is that all relevant activities are progressing well and the company remains on track to filing an... More
Sarepta Therapeutics (SRPT) CEO Chris Garabedian Speaks on CNBC
August 5, 2014 5:50 PM EDTSarepta Therapeutics (NASDAQ: SRPT) was active Tuesday following comment from CEO Chris Garabedian on CNBC.
... MoreSarepta Therapeutics (SRPT) Sees Upside
August 5, 2014 12:57 PM EDTSarepta Therapeutics (NASDAQ: SRPT) sees upside on volume. Shares up 2.9%.
... More